Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer
About firstname.lastname@example.orgThis author has not yet filled in any details.
So far email@example.com has created 4 blog entries.
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR firstname.lastname@example.orgT12:55:52+00:00
*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains
*November 7, 2018* Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with
By Donna Fernandez · November 9, 2018. I generally begin November by listing, day by day, that for which I am grateful. Some days, the